Sequential Treatment with Bevacizumab and Aflibercept for
Metastatic Colorectal Cancer in Real-World Clinical Practice

J 2020

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice

BUCHLER, Tomas; Igor KISS; Jana HORNOVA; Ondrej FIALA; Marketa WIESNEROVA et al.

Základní údaje

Originální název

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice

Autoři

BUCHLER, Tomas; Igor KISS; Jana HORNOVA; Ondrej FIALA; Marketa WIESNEROVA; Michal SVOBODA; Jiri SILAR; Katerina KOPECKOVA; Alexandr POPRACH; Jindrich FINEK; Lubos PETRUZELKA a Bohuslav MELICHAR

Vydání

Targeted Oncology, Dordrecht, Springer, 2020, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.493

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116027

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

SIAN PATIENTS; SAFETY; FLUOROURACIL; COMBINATION; LEUCOVORIN; IRINOTECAN; EFFICACY

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 7. 2020 10:07, Mgr. Tereza Miškechová

Anotace

V originále

Background Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. Objective The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. Patients and Methods Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. Results Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. Conclusions Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.

Citovat

BUCHLER, Tomas; Igor KISS; Jana HORNOVA; Ondrej FIALA; Marketa WIESNEROVA; Michal SVOBODA; Jiri SILAR; Katerina KOPECKOVA; Alexandr POPRACH; Jindrich FINEK; Lubos PETRUZELKA a Bohuslav MELICHAR. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology. Dordrecht: Springer, 2020, roč. 15, č. 2, s. 193-201. ISSN 1776-2596. Dostupné z: https://doi.org/10.1007/s11523-020-00705-1.

@article{1670613,
   author = {Buchler, Tomas and Kiss, Igor and Hornova, Jana and Fiala, Ondrej and Wiesnerova, Marketa and Svoboda, Michal and Silar, Jiri and Kopeckova, Katerina and Poprach, Alexandr and Finek, Jindrich and Petruzelka, Lubos and Melichar, Bohuslav},
   article_location = {Dordrecht},
   article_number = {2},
   doi = {https://doi.org/10.1007/s11523-020-00705-1},
   keywords = {SIAN PATIENTS; SAFETY; FLUOROURACIL; COMBINATION; LEUCOVORIN; IRINOTECAN; EFFICACY},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice},
   url = {https://link.springer.com/article/10.1007%2Fs11523-020-00705-1},
   volume = {15},
   year = {2020}
}

TY  - JOUR
ID  - 1670613
AU  - Buchler, Tomas - Kiss, Igor - Hornova, Jana - Fiala, Ondrej - Wiesnerova, Marketa - Svoboda, Michal - Silar, Jiri - Kopeckova, Katerina - Poprach, Alexandr - Finek, Jindrich - Petruzelka, Lubos - Melichar, Bohuslav
PY  - 2020
TI  - Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice
JF  - Targeted Oncology
VL  - 15
IS  - 2
SP  - 193-201
EP  - 193-201
PB  - Springer
SN  - 17762596
KW  - SIAN PATIENTS
KW  - SAFETY
KW  - FLUOROURACIL
KW  - COMBINATION
KW  - LEUCOVORIN
KW  - IRINOTECAN
KW  - EFFICACY
UR  - https://link.springer.com/article/10.1007%2Fs11523-020-00705-1
L2  - https://link.springer.com/article/10.1007%2Fs11523-020-00705-1
N2  - Background Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. Objective The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. Patients and Methods Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. Results Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. Conclusions Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.
ER  -

BUCHLER, Tomas; Igor KISS; Jana HORNOVA; Ondrej FIALA; Marketa WIESNEROVA; Michal SVOBODA; Jiri SILAR; Katerina KOPECKOVA; Alexandr POPRACH; Jindrich FINEK; Lubos PETRUZELKA a Bohuslav MELICHAR. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. \textit{Targeted Oncology}. Dordrecht: Springer, 2020, roč.~15, č.~2, s.~193-201. ISSN~1776-2596. Dostupné z: https://doi.org/10.1007/s11523-020-00705-1.

Přehled o publikaci